Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone973-557-8914
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
OptionableNot Optionable
Regenicin (OTCMKTS:RGIN) Frequently Asked Questions
What is Regenicin's stock symbol?
Regenicin trades on the OTCMKTS under the ticker symbol "RGIN."
When is Regenicin's next earnings date?
Has Regenicin been receiving favorable news coverage?
News articles about RGIN stock have been trending positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regenicin earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Regenicin's key competitors?
Some companies that are related to Regenicin include Avinger (AVGR), Valeritas (VLRX), Presbia (LENS), United American Healthcare (UAHC), Atossa Genetics (ATOS), Neurometrix (NURO), CELLECT BIOTECH/S (APOP), Viatar CTC Solutions (VRTT), Encision (ECIA), Delcath Systems (DCTH), Cytori Therapeutics (CYTX), Amedica (AMDA), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB) and Calmare Therapeutics (CTTC).
Who are Regenicin's key executives?
Regenicin's management team includes the folowing people:
- Mr. Randall McCoy, Chairman, CEO & Pres (Age 70)
- Mr. John J. Weber, CFO & Director (Age 69)
- Dr. J. Roy Nelson, Chief Science Officer (Age 71)
- Mr. Richard Koeninger M.S, Director of Regulatory Affairs (Age 79)
- Ms. Lauri-Ann Hahn R.N. B.S.N, Director of Clinical Trials (Age 48)
How do I buy shares of Regenicin?
Shares of RGIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenicin's stock price today?
One share of RGIN stock can currently be purchased for approximately $0.0177.
How big of a company is Regenicin?
Regenicin has a market capitalization of $2.72 million. Regenicin employs 3 workers across the globe.
What is Regenicin's official website?
How can I contact Regenicin?
Regenicin's mailing address is 10 HIGH COURT, LITTLE FALLS NJ, 07424. The company can be reached via phone at 973-557-8914.
MarketBeat Community Rating for Regenicin (OTCMKTS RGIN)
MarketBeat's community ratings are surveys of what our community members think about Regenicin and other stocks. Vote "Outperform" if you believe RGIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
